Physician profile
David G Sharp
NPI 1932117470
$26,473.09
in general payments reported to CMS, 2019-2025
82 companies · $3,827 in 2025
The $3,827 reported for 2025 was more than what 97% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,867 · 2020: $3,593 · 2021: $4,358 · 2022: $3,103 · 2023: $3,871 · 2024: $3,855 · 2025: $3,827.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $11K · Education: $171.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $11,381.24 |
| Education | $171.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $3,524.19 | 2019-2025 | Repatha, Otezla, Evenity |
| Abbvie INC. | $2,302.93 | 2020-2025 | Ubrelvy, Qulipta, Vraylar |
| Astrazeneca Pharmaceuticals Lp | $2,130.10 | 2019-2025 | Farxiga, Xigduo, Airsupra |
| Antares Pharma, INC. | $2,092.46 | 2019-2025 | Xyosted, Tlando, Nocdurna |
| Gilead Sciences, INC. | $1,892.93 | 2019-2025 | Epclusa |
| Novartis Pharmaceuticals Corporation | $1,885.33 | 2019-2025 | |
| Lilly USA, LLC | $1,625.48 | 2019-2025 | Mounjaro, Kisunla, Jardiance |
| Novo Nordisk INC | $1,289.90 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Amarin Pharma, INC. | $1,232.21 | 2019-2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $520.19 | 2022-2025 | |
| Pfizer INC. | $497.08 | 2020-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $467.07 | 2019-2025 | |
| Kowa Pharmaceuticals America, INC. | $461.76 | 2019-2023 | Livalo, Seglentis |
| Sanofi-Aventis U.S. LLC | $410.62 | 2019-2024 | |
| Biohaven Pharmaceuticals, INC. | $375.87 | 2020-2021 |
Show all 82 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Sharp listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.